Rapid success of first program leads to second collaboration to develop optimized enzyme for large scale manufacturing process Enzyme development
The agreement with Kalsec anticipates milestone payments for finalizing research and development work and a royalty stream for Willow upon
Company reports record revenue of $1.0 million, an increase of approximately 600% over the second quarter of 2023 Signed strategic
After a successful feasibility study, Company expands into the high growth biopesticide sector with a funded research and development program
Sunnyvale, California – July 26, 2024 – Willow Biosciences Inc.(“Willow” or the “Company“) (TSX: WLLW; OTCQB: CANSF) is pleased to announce
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES ORFOR DISSEMINATION IN THE UNITED STATES Calgary, Alberta – July 18, 2024 –
Phone: +1 403 910 5140
Email: info@willowbio.com
© 2023 Willow Biosciences Inc.
Powered by BragDeal Inc.
Focused on identifying and deploying additional genetic elements and solutions to further enhance production of our yeast strains and processes. This state-of-the-art R&D facility includes high-throughput molecular biology and screening technologies, high-end analytical instrumentation and fermentation capabilities along with systems to rapidly evaluate high volumes of data and results.